Suchen
EyePoint Pharmaceuticals Inc
EYPTZur Watchlist hinzufügen
13.980USD
+0.785+5.95%
Handelsschluss 07/02, 13:00（ET）Kurse um 15 Minuten verzögert
1.16BMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über EyePoint Pharmaceuticals Inc Unternehmen
EyePoint Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing innovative therapeutics to help improve the lives of patients with serious retinal diseases. The Company’s lead product candidate, DURAVYU, is an investigational sustained delivery treatment for anti-vascular endothelial growth factor (anti-VEGF) mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E. DURAVYU is presently in Phase 3 global, pivotal clinical trials for wet age-related macular degeneration (wet AMD). Additional pipeline programs include EYP-2301, a promising TIE-2 agonist, razuprotafib, formulated in Durasert E to potentially improve outcomes in serious retinal diseases. The Company’s other products include YUTIQ and DEXYCU.
EyePoint Pharmaceuticals Inc Informationen
BörsenkürzelEYPT
Name des UnternehmensEyePoint Pharmaceuticals Inc
IPO-datumJan 27, 2005
CEODuker (Jay S)
Anzahl der mitarbeiter165
WertpapierartOrdinary Share
GeschäftsjahresendeJan 27
Addresse480 Pleasant Street, Suite C400
StadtWATERTOWN
BörseNASDAQ OMX - NASDAQ BASIC
LandUnited States of America
Postleitzahl02472
Telefon16179265000
Websitehttps://eyepointpharma.com/
BörsenkürzelEYPT
IPO-datumJan 27, 2005
CEODuker (Jay S)
Führungskräfte von EyePoint Pharmaceuticals Inc
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Jay S. Duker, M.D.
Dr. Jay S. Duker, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
944.09K
+28.33%
Ms. Nancy S. Lurker
Ms. Nancy S. Lurker
Executive Vice Chairman of the Board
Executive Vice Chairman of the Board
649.85K
-0.52%
Dr. John B. Landis, Ph.D.
Dr. John B. Landis, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
182.86K
+21.87%
Ms. Karen L. Zaderej
Ms. Karen L. Zaderej
Non-Executive Independent Director
Non-Executive Independent Director
164.61K
+28.75%
Mr. Stuart Duty
Mr. Stuart Duty
Non-Executive Independent Director
Non-Executive Independent Director
105.01K
+57.14%
Mr. Ramiro Ribeiro, M.D., Ph.D.
Mr. Ramiro Ribeiro, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
75.19K
+48.05%
Mr. Fred Hassan
Mr. Fred Hassan
Non-Executive Independent Director
Non-Executive Independent Director
60.00K
--
Dr. Goeran A. Ando, M.D.
Dr. Goeran A. Ando, M.D.
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Ms. Wendy F. Dicicco, CPA
Ms. Wendy F. Dicicco, CPA
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. George Elston
Mr. George Elston
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Jay S. Duker, M.D.
Dr. Jay S. Duker, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
944.09K
+28.33%
Ms. Nancy S. Lurker
Ms. Nancy S. Lurker
Executive Vice Chairman of the Board
Executive Vice Chairman of the Board
649.85K
-0.52%
Dr. John B. Landis, Ph.D.
Dr. John B. Landis, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
182.86K
+21.87%
Ms. Karen L. Zaderej
Ms. Karen L. Zaderej
Non-Executive Independent Director
Non-Executive Independent Director
164.61K
+28.75%
Mr. Stuart Duty
Mr. Stuart Duty
Non-Executive Independent Director
Non-Executive Independent Director
105.01K
+57.14%
Mr. Ramiro Ribeiro, M.D., Ph.D.
Mr. Ramiro Ribeiro, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
75.19K
+48.05%
Häufig gestellte Fragen
Wer sind die fünf größten Anteilseigner von EyePoint Pharmaceuticals Inc?
Die fünf größten Anteilseigner von EyePoint Pharmaceuticals Inc sind: Dr. Jay S. Duker, M.D.
Wie viele Institutionen halten Anteile an EyePoint Pharmaceuticals Inc (EYPT)?
Mit Stand vom 2026Q1 halten 381 Institutionen Anteile an EyePoint Pharmaceuticals Inc, mit einem Gesamtmarktwert von etwa 88.53M, was 105.59% der Gesamtanteile entspricht. Im Vergleich zum 2025Q4 ist der institutionelle Aktienbesitz um -2754490.00 gestiegen.
Was ist die größte Einnahmequelle von EyePoint Pharmaceuticals Inc?
Am 2026Q1 erzielte das Geschäft mit YUTIQ für EyePoint Pharmaceuticals Inc den höchsten Umsatz in Höhe von 1.60M, was 5.10% des Gesamtumsatzes entspricht.